Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | PSMA vs AXUMIN PET/CT in prostate cancer

Jeremie Calais • 2 Jun 2019
ASCO 2019
Genitourinary Cancer Prostate Cancer

Jeremie Calais, MD, from the University of California, Los Angeles, CA, talks about 18F-fluciclovine (AXUMIN) vs 68Ga-PSMA-11 (PSMA) PET/CT molecular imaging in prostate cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Jeremie Calais

2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
4:16
PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting
Jeremie Calais • 3 Jun 2023
2:10
Integrating radioligand therapy for prostate cancer in US clinical practice
Jeremie Calais • 4 Jun 2023
2:56
PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
Jeremie Calais • 4 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals